Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Xspray Pharma AB ( (SE:XSPRAY) ).
Xspray Pharma AB’s annual general meeting approved the company’s 2025 financial statements, discharged the board and CEO from liability, and decided to retain earnings by not paying a dividend. Shareholders also re-elected the entire board, confirmed KPMG AB as auditor, set remuneration in line with the nomination committee’s proposals, and reaffirmed the principles for appointing the nomination committee.
The AGM adopted two new long-term incentive programs for employees, one based on warrants and stock options and another on performance-based share rights, which includes introducing a new class of reclassifiable and redeemable shares. The board was additionally authorised to issue new shares, warrants, and convertibles of up to 20% of current share capital, strengthening Xspray’s flexibility to finance future growth and align employee incentives with long-term shareholder value.
More about Xspray Pharma AB
Xspray Pharma AB is a Swedish pharmaceutical company focused on developing improved versions of existing cancer therapies using its patented technology platforms. The company targets oncology markets by creating enhanced oral formulations intended to offer more precise dosing and potentially better safety and efficacy profiles for patients.
Average Trading Volume: 66,775
Technical Sentiment Signal: Sell
Current Market Cap: SEK1.1B
See more data about XSPRAY stock on TipRanks’ Stock Analysis page.